{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:31:18Z","timestamp":1794918678107,"version":"4.9.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.vaccine.2010.12.039","type":"journal-article","created":{"date-parts":[[2011,1,4]],"date-time":"2011-01-04T09:11:54Z","timestamp":1294132314000},"page":"1413-1420","source":"Crossref","is-referenced-by-count":125,"title":["A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression"],"prefix":"10.1016","volume":"29","author":[{"given":"P.B.","family":"Keiser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Biggs-Cicatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.E.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.H.","family":"Schmiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.B.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.E.","family":"Burden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.B.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.D.","family":"Zollinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2010.12.039_bib0005","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1084\/jem.129.6.1349","article-title":"Human immunity to the meningococcus: III. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides","volume":"129","author":"Gotschlich","year":"1969","journal-title":"J Exp Med"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2010.12.039_bib0010","doi-asserted-by":"crossref","first-page":"B42","DOI":"10.1016\/j.vaccine.2009.05.001","article-title":"Meningococcal protein antigens and vaccines","volume":"27","author":"Feavers","year":"2009","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2010.12.039_bib0015","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0020","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1128\/IAI.00411-07","article-title":"Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis","volume":"75","author":"Weynants","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0025","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B. meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2010.12.039_bib0030","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1086\/648966","article-title":"Review of meningococcal group B vaccines","volume":"50","author":"Granoff","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0035","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.1016\/j.vaccine.2010.08.048","article-title":"A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA","volume":"28","author":"Keiser","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0180","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1016\/j.vaccine.2010.05.006","article-title":"Design and evaluation in animals of a broadly protective meningococcal group B Native outer membrane vesicle vaccine","volume":"28","author":"Zollinger","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0045","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1128\/CVI.00342-09","article-title":"Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants","volume":"17","author":"Stoddard","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0050","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1099\/00222615-41-4-236","article-title":"Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies","volume":"41","author":"Scholten","year":"1994","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0055","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1016\/S0021-9258(19)39105-7","article-title":"Structure of the L5 lipopolysaccharide core oligosaccharides of Neisseria meningitidis","volume":"265","author":"Michon","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0060","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0065","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1128\/CVI.00255-09","article-title":"Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity","volume":"16","author":"Zollinger","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0070","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0022-1759(81)90130-7","article-title":"A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies","volume":"46","author":"Zollinger","year":"1981","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1128\/IAI.67.1.113-119.1999","article-title":"Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice","volume":"67","author":"Saunders","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0080","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.1016\/j.vaccine.2009.09.019","article-title":"Plasma fibrinogen levels after vaccination with a native outer membrane vesicle vaccine for Neisseria meningitidis","volume":"27","author":"Keiser","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0085","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1128\/IAI.62.12.5290-5295.1994","article-title":"Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity","volume":"62","author":"Moran","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0090","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4161\/hv.6.4.11055","article-title":"Whole cell vaccination for meningococcus: lessons from an idea whose time has gone","volume":"6","author":"Labrie","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0095","series-title":"Applied immunology: the practical application of sera and bacterins prophylactically, diagnostically and therapeutically","article-title":"Bacterial inoculation: cerebrospinal meningitis","author":"Thomas","year":"1915"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0105","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0115","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0120","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/infdis\/167.5.1065","article-title":"The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies","volume":"167","author":"Rosenqvist","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0125","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1128\/IAI.69.6.3809-3816.2001","article-title":"Immunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci","volume":"69","author":"Jolley","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0130","series-title":"Vaccine adjuvants and delivery systems","first-page":"131","article-title":"TLR4 agonists as vaccine adjuvants","author":"Johnson","year":"2007"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0135","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0264-410X(99)00381-3","article-title":"Biological activities of antibodies elicited by lipooligosaccharide based-conjugate vaccines of nontypeable Haemophilus influenzae in an otitis media model","volume":"18","author":"Sun","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0140","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1128\/IAI.68.3.1529-1534.2000","article-title":"Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam","volume":"68","author":"Konadu","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0145","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.vaccine.2003.11.025","article-title":"Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis","volume":"22","author":"Cross","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0150","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1016\/S0264-410X(03)00483-3","article-title":"Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)\/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects","volume":"21","author":"Cross","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0155","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/S0264-410X(02)00768-5","article-title":"Phase I study of a lipooligosaccharide-based conjugate vaccine against nontypeable Haemophilus influenzae","volume":"21","author":"Gu","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0165","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.vaccine.2008.11.046","article-title":"Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity","volume":"27","author":"de Vries","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0170","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1080\/10611860802295607","article-title":"Enhancement of T-helper type I immune responses against hepatitis B surface antigen by LPS derivatives adjuvanted liposomes delivery system","volume":"16","author":"Jain","year":"2008","journal-title":"J Drug Target"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0175","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1128\/IAI.00005-08","article-title":"Differential activation of human and mouse Toll-like receptor 4 by the adjuvant candidate LpxL1 of Neisseria meningitidis","volume":"76","author":"Steeghs","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2010.12.039_bib0185","unstructured":"Koeberling O, Delany I, Granoff DM. A critical threshold of meningococcal fHbp expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle (NOMV) vaccines prepared from mutants. In: Program and Abstract Guide: IPNC 2010, 17th International Pathogenic Neisseria Conference. Banff, Canada; 2010. p. 69."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10018128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10018128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T21:02:18Z","timestamp":1637096538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10018128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0264410X10018128"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.12.039","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}